Trial reportMolecular psychiatry2008
Genomewide association for schizophrenia in the CATIE study: results of stage 1.
Trial report in Molecular psychiatry, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to trial NCT01245348 (Relative Effectiveness of Schizophrenia Therapy), which is not on this map. Cited by 182 papers, 7 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Relative Effectiveness of Schizophrenia Therapy (REST) Study
Who cites it
182 citing papers in PubMed, 7 syntheses or guidelines pooled it.
- Machine Learning and Pharmacogenomics at the Time of Precision Psychiatry.Current neuropharmacology · 2023Pooled it
- Association between aBioMed research international · 2020Pooled it
- Reciprocal duplication of the Williams-Beuren syndrome deletion on chromosome 7q11.23 is associated with schizophrenia.Biological psychiatry · 2014Pooled it
- GWA study data mining and independent replication identify cardiomyopathy-associated 5 (CMYA5) as a risk gene for schizophrenia.Molecular psychiatry · 2011Pooled it
- Pooled it
- Cytochrome P450 testing for prescribing antipsychotics in adults with schizophrenia: systematic review and meta-analyses.The pharmacogenomics journal · 2011Pooled it
- The DISC locus and schizophrenia: evidence from an association study in a central European sample and from a meta-analysis across different European populations.Human molecular genetics · 2009Pooled it
- The GRM7 gene, early response to risperidone, and schizophrenia: a genome-wide association study and a confirmatory pharmacogenetic analysis.The pharmacogenomics journal · 2017Trial
- Genotypic variation in the SV2C gene impacts response to atypical antipsychotics the CATIE study.Schizophrenia research · 2013Trial
- Genome-wide association study of patient-rated and clinician-rated global impression of severity during antipsychotic treatment.Pharmacogenetics and genomics · 2013Trial
- Influence of ANKK1 and DRD2 polymorphisms in response to haloperidol.European archives of psychiatry and clinical neuroscience · 2013Trial
- Genetic variation in CYP3A43 explains racial difference in olanzapine clearance.Molecular psychiatry · 2011Trial
- Genomewide pharmacogenomic study of metabolic side effects to antipsychotic drugs.Molecular psychiatry · 2011Trial
- Genome-wide pharmacogenomic analysis of response to treatment with antipsychotics.Molecular psychiatry · 2011Trial
- Common promoter variants of the NDUFV2 gene do not confer susceptibility to schizophrenia in Han Chinese.Behavioral and brain functions : BBF · 2010Trial
- A systematic method for estimating individual responses to treatment with antipsychotics in CATIE.Schizophrenia research · 2009Trial
- SNP-based prediction of schizophrenia using machine learning.Bioinformatics advances · 2026Article
- Plasma profiles of neurology-related proteins in at-risk mental state and first-episode psychosis: Associations with psychotic symptoms and cognitive performance.Brain, behavior, & immunity - health · 2025Article
- A review of post-GWAS studies in schizophrenia.Translational psychiatry · 2025Review
- Classification of schizophrenia, bipolar disorder and major depressive disorder with comorbid traits and deep learning algorithms.Schizophrenia (Heidelberg, Germany) · 2025Article
122 more citing papers are in PubMed but not listed here.
Corrections and comments
- Erratum issued
Authors and funding
14 authors.
Funding
Abstract
Little is known for certain about the genetics of schizophrenia. The advent of genomewide association has been widely anticipated as a promising means to identify reproducible DNA sequence variation associated with this important and debilitating disorder. A total of 738 cases with DSM-IV schizophrenia (all participants in the CATIE study) and 733 group-matched controls were genotyped for 492,900 single-nucleotide polymorphisms (SNPs) using the Affymetrix 500K two-chip genotyping platform plus a custom 164K fill-in chip. Following multiple quality control steps for both subjects and SNPs, logistic regression analyses were used to assess the evidence for association of all SNPs with schizophrenia. We identified a number of promising SNPs for follow-up studies, although no SNP or multimarker combination of SNPs achieved genomewide statistical significance. Although a few signals coincided with genomic regions previously implicated in schizophrenia, chance could not be excluded. These data do not provide evidence for the involvement of any genomic region with schizophrenia detectable with moderate sample size. However, a planned genomewide association study for response phenotypes and inclusion of individual phenotype and genotype data from this study in meta-analyses hold promise for eventual identification of susceptibility and protective variants.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.